Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.63 |
| ▸ | EGFR | P00533 | 13/20 | 0.63 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.63 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.63 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.63 |
| ▸ | PRKDC | P78527 | 12/20 | 0.63 |
| ▸ | ABL1 | P00519 | 11/20 | 0.63 |
| ▸ | HCK | P08631 | 11/20 | 0.63 |
| ▸ | SRC | P12931 | 11/20 | 0.63 |
| ▸ | MTOR | P42345 | 11/20 | 0.63 |
| ▸ | EPHB4 | P54760 | 11/20 | 0.63 |
| ▸ | PI4KB | Q9UBF8 | 9/20 | 0.63 |
| ▸ | RET | P07949 | 4/20 | 0.55 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.46 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1321276 | 1.00 | KDR (0.63) | KDREGFRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1320199 | 1.00 | KDR (0.63) | KDREGFRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL24096737 | 0.94 | PIK3CD (0.55) | KDREGFRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL24096491 | 0.92 | PIK3CD (0.52) | KDREGFRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL24096494 | 0.88 | SRC (0.58) | KDREGFRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL30320566 | 0.88 | SRC (0.58) | KDREGFRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL24096513 | 0.86 | PIK3CD (0.62) | KDREGFRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1317762 | 0.86 | PIK3CD (0.65) | KDREGFRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL30320584 | 0.86 | PIK3CD (0.62) | KDREGFRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1319000 | 0.86 | KDR (0.71) | KDREGFRPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| CN-116075513-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-4161933-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2021252488-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-2358720-B1 | FUSED RING HETEROARYL KINASE INHIBITORS | UNIV CALIFORNIA (US) | 2016-03-02 | — | — | EP | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8697709-B2 | Fused ring heteroaryl kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2358720-A2 | FUSED RING HETEROARYL KINASE INHIBITORS | The Regents of the University of California (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010045542-A2 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | KDR 4072/4885EGFR 4664/4885PIK3CD 1435/4885 |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | XBP1, DNAJC10, HSPA5 | KDR 4859/4885EGFR 4349/4885PIK3CD 2956/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | KDR 4751/4885EGFR 4872/4885PIK3CD 3373/4885 |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | CNKSR1, MAP3K20, TTK | KDR 837/4885EGFR 985/4885PIK3CD 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.